Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies

Author:

Daviglus Martha L.1ORCID,Ferdinand Keith C.2,López J. Antonio G.3ORCID,Wu You3ORCID,Monsalvo Maria Laura3ORCID,Rodriguez Carlos J.4ORCID

Affiliation:

1. University of Illinois at Chicago IL

2. Tulane University New Orleans LA

3. Global Development Amgen Inc. Thousand Oaks CA

4. Albert Einstein College of Medicine New York NY

Abstract

Background Prevalence of cardiovascular disease risk factors and rates of atherosclerotic cardiovascular disease outcomes vary across racial/ethnic groups. This analysis examined the effects of evolocumab on LDL‐C (low‐density lipoprotein cholesterol) levels and LDL‐C goals achievement by race/ethnicity. Methods and Results Data from 15 phase 2 and 3 studies of treatment with evolocumab versus placebo or ezetimibe were pooled (n=7669). Results were analyzed by participant clinical characteristics and by self‐identified race/ethnicity. Key outcomes included percent change from baseline in LDL‐C, achievement of LDL‐C <70 mg/dL, and LDL‐C reduction of ≥50% at 12 weeks and at 1 to 5 years. Across 12‐week studies, mean percent change in LDL‐C from baseline in evolocumab‐treated participants was −52% to −59% for White and −46% to −67% for non‐White participants, across clinical characteristics groups. LDL‐C <70 mg/dL was achieved in 43% to 84% and 62% to 94% and LDL‐C reduction of ≥50% in 63% to 78% and 58% to 86%, respectively. In 1‐ to 5‐year studies, mean percent change in LDL‐C was −46% to −52% for White and −49% to −55% for non‐White participants. LDL‐C <70 mg/dL was achieved in 53% to 84% and 66% to 77%, and LDL‐C reduction of ≥50% in 53% to 67% and 58% to 68%, respectively. The treatment effect on mean percent change in LDL‐C differed only in participants with type 2 diabetes mellitus, with a larger reduction in Asian participants. The qualitative interaction P values were nonsignificant, indicating consistent directionality of effect. Conclusions Similar reduction in LDL‐C levels with evolocumab was observed across racial/ethnic groups in 12‐week and 1‐ to 5‐year studies. Among those with diabetes mellitus, Asian participants had greater LDL‐C reduction.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3